Daily Ards Research Analysis
Three impactful ARDS studies emerged: a PROSPERO-registered meta-analysis suggests stem cell-based therapies reduce short-term mortality and are well tolerated; a randomized crossover trial shows two transpulmonary pressure-based PEEP titration strategies yield discordant patient-level PEEP without physiologic superiority; and a large retrospective cohort indicates mechanical power normalized to compliance better discriminates ICU mortality risk. Together, they advance cell therapy translation a
Summary
Three impactful ARDS studies emerged: a PROSPERO-registered meta-analysis suggests stem cell-based therapies reduce short-term mortality and are well tolerated; a randomized crossover trial shows two transpulmonary pressure-based PEEP titration strategies yield discordant patient-level PEEP without physiologic superiority; and a large retrospective cohort indicates mechanical power normalized to compliance better discriminates ICU mortality risk. Together, they advance cell therapy translation and precision ventilation.
Research Themes
- Cell-based therapies and extracellular vesicles in ARDS
- Personalized ventilation using transpulmonary pressure and mechanical power
- Translational metrics for outcome prediction in critical care
Selected Articles
1. Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis.
This PROSPERO-registered meta-analysis of 31 studies found that MSC-based therapies and their derivatives reduced all-cause mortality within 1 month in ARDS (RR 0.74; I²=5%) and were well tolerated. Benefit appeared confined to short-term mortality, with signals that higher MSC doses may be more effective.
Impact: Provides the most comprehensive synthesis to date indicating short-term mortality reduction and safety of stem cell-based interventions in ARDS, guiding trial design and dosing strategies.
Clinical Implications: Supports continued clinical development of MSC/EV therapies with emphasis on optimizing dose and timing, and prioritizing adequately powered RCTs focusing on 28–30 day mortality and standardized manufacturing.
Key Findings
- Across 31 included studies, stem cell-based therapies reduced all-cause mortality within 1 month versus routine care (RR 0.74, 95% CI 0.62–0.89; low heterogeneity I²=0–5%).
- Therapeutic benefit was confined to short-term mortality; effects beyond one month were not demonstrated.
- Higher MSC dosing showed signals of greater efficacy; therapies were generally well tolerated with acceptable AE/SAE profiles.
Methodological Strengths
- PROSPERO registration with predefined protocol and comprehensive multi-database search
- Low heterogeneity for primary outcome and subgroup analyses by study design, ARDS etiology, therapy type, and dosing
Limitations
- Many included trials were small and some nonrandomized, raising risk of bias and imprecision
- Benefit limited to short-term mortality; longer-term outcomes and functional recovery remain unclear
Future Directions: Conduct large, rigorously blinded, multi-center RCTs with standardized cell sourcing/manufacturing, dose-finding arms, and biomarker-driven enrichment to validate survival benefit and define responders.
BACKGROUND: Although numerous clinical trials have explored stem cell-based therapies for acute respiratory distress syndrome (ARDS), their findings are inconsistent. This meta-analysis aimed to comprehensively evaluate the efficacy and safety of stem cell-based therapies, including mesenchymal stem/stromal cells (MSCs) and their derived extracellular vesicles (EVs), in the treatment of ARDS. METHODS: A comprehensive literature search of the Cochrane Library, PubMed, and Web of Science databases and the US National Institutes of Health Trials Registry (ClinicalTrials.gov) was conducted to identify eligible studies assessing the efficacy and safety of stem cell-based therapies in ARDS. The primary outcomes included all-cause mortality within or over one month, adverse events (AEs), and serious adverse events (SAEs). To explore possible bias, subgroup analysis was performed based on the design of study (randomized controlled trial vs. nonrandomized interventional trial), etiology of ARDS, type of stem cell-based therapy, and times of infusion. Relative risk (RR) and mean difference (MD) were calculated to evaluate efficacy and safety. This study was registered with PROSPERO (CRD42024593740). RESULTS: A total of 48 studies involving 1,773 patients were eligible, of which 31 studies were included in the meta-analysis. The results revealed a significant reduction in all-cause mortality among patients receiving MSCs or their derived EVs and secretomes compared to those receiving routine therapy (RR = 0.74, 95% CI = 0.63-0.87, p = 0.0003, I²=5%). This effect was only seen in all-cause mortality within one month (RR = 0.74, 95% CI = 0.62-0.89, p = 0.002, I²=0%); furthermore, high dose MSCs (over 1 × 10 CONCLUSIONS: Stem cell-based therapy significantly reduced mortality within one month and was well tolerated in ARDS patients. Given the limited sample size of included studies, the efficacy of stem cell-based therapy in patients with ARDS needs to be validated in further larger and more rigorous randomized controlled trials.
2. Comparison of two transpulmonary pressure-based positive end-expiratory pressure titration strategies in acute respiratory distress syndrome: a randomized crossover study.
In a randomized crossover physiological trial of 20 moderate-to-severe ARDS patients, two transpulmonary pressure-based PEEP titration strategies yielded similar median PEEP but divergent patient-level values, often differing by ≥3 cmH2O. Neither approach improved recruited lung volume or reduced estimated stress/strain.
Impact: First head-to-head randomized comparison of transpulmonary pressure-based PEEP strategies, highlighting substantial individual variability and lack of clear physiologic superiority.
Clinical Implications: Clinicians should avoid assuming equivalence at the bedside; transpulmonary-based PEEP strategies may set materially different PEEP in individual patients without demonstrable physiological benefit, underscoring the need for multimodal assessment and outcome-focused trials.
Key Findings
- Two transpulmonary pressure-based PEEP titration strategies produced similar median PEEP but uncorrelated patient-level values, frequently differing by ≥3 cmH2O.
- Neither strategy increased recruited lung volume nor reduced estimated stress and strain.
- Trial was prospectively registered (NCT03281473), strengthening methodological transparency.
Methodological Strengths
- Randomized crossover design minimizing inter-individual confounding
- Esophageal pressure monitoring enabling direct transpulmonary pressure estimation and trial registration
Limitations
- Small sample size with short-term physiological endpoints; no clinical outcomes
- Incomplete reporting in abstract of exact thresholds and parameter distributions limits external interpretation
Future Directions: Integrate imaging, lung recruitability indices, and outcome endpoints to test whether transpulmonary-guided PEEP improves survival or ventilator-free days and to define patient subgroups benefiting from each strategy.
BACKGROUND: Esophageal pressure monitoring, which enables the estimation of transpulmonary pressure, has been proposed to personalize ventilator settings, particularly positive end-expiratory pressure (PEEP), in patients with acute respiratory distress syndrome (ARDS). Two conceptually different transpulmonary pressure-based PEEP titration strategies have thus been described but have never been compared. This study aims to compare the PEEP levels obtained with these two distinct strategies and their physiological effects. METHODS: This was a randomized crossover physiological study. Twenty patients with moderate to severe ARDS (PaO RESULTS: Median PEEP levels determined by the two strategies were not different; however, individual values were uncorrelated, with a difference of at least 3 cmH CONCLUSIONS: The two transpulmonary pressure-based titration strategies result in different PEEP levels in most patients. Neither strategy is associated with higher recruited lung volume or lower estimated Stress and Strain. TRIAL REGISTRATION: #NCT03281473 Clinicaltrials.gov. Registered 12 September 2017.
3. Mechanical power normalisation methods to predict ICU mortality: a retrospective cohort study.
In 3,578 mechanically ventilated adults, mechanical power normalized to respiratory system compliance had superior discrimination for ICU mortality (AUROC 0.71; p=0.007 vs comparators). Normalization strategies reflecting individual susceptibility to VILI improved prognostic performance over raw MP.
Impact: Defines a pragmatic, physiology-informed normalization of mechanical power that outperforms raw MP for mortality prediction, informing personalized ventilation risk stratification.
Clinical Implications: Compliance-normalized mechanical power may guide safer ventilator settings and risk stratification; implementing this metric in ICU dashboards could improve recognition of injurious ventilation.
Key Findings
- Among 3,578 ventilated adults, compliance-normalized mechanical power achieved AUROC 0.71 (95% CI 0.69–0.73) for ICU mortality and outperformed alternative normalizations.
- Normalization to physiologically relevant variables improved prognostic discrimination compared with raw mechanical power.
- Granular EHR data over seven years enabled robust comparison across normalization methods.
Methodological Strengths
- Large single-center cohort with granular ventilator and gas exchange data
- Comparative evaluation of multiple normalization strategies with AUROC and statistical testing
Limitations
- Retrospective single-center design susceptible to unmeasured confounding and practice patterns
- Causality cannot be inferred; clinical utility requires prospective validation and threshold definition
Future Directions: Prospective multicenter validation to test whether compliance-normalized mechanical power reduces VILI and improves outcomes when used to guide ventilator adjustments.
BACKGROUND: The optimal mechanical ventilation strategy to minimise ventilator-induced lung injury (VILI) remains uncertain. Mechanical power (MP) is a key VILI determinant, but whether and how MP should be normalised to individual patient characteristics is unclear. In this study, we aimed to evaluate whether the discriminatory accuracy of MP for ICU mortality in mechanically ventilated patients improves when normalised to physiologically relevant variables that reflect individual susceptibility to VILI. We also explored whether the relationship between MP, MP METHODS: In this retrospective observational study, we extracted granular electronic healthcare record data for mechanically ventilated adults in a single centre over a seven-year period. Primary exposures were MP with five normalisations: for dead space (expressed as corrected minute ventilation, ventilatory ratio, or end-tidal to arterial CO RESULT: We included 3,578 patients in our analyses. We found MP normalised to compliance (AUROC 0.71, 95% confidence interval (CI) 0.69-0.73, p = 0.007 (DeLong's test)) and MP CONCLUSIONS: Mechanical power normalised to compliance and MP